MedKoo product information:

 Ondansetron Hydrochloride

ondansetron hydrochloride is the hydrochloride salt of the racemic form of ondansetron, a carbazole derivative and a selective, competitive serotonin 5-hydroxytrptamine type 3 (5-HT3) receptor antagonist with antiemetic activity. Although its mechanism of action has not been fully characterized, ondansetron appears to competitively block the action of serotonin at 5HT3 receptors peripherally in the gastrointestinal tract as well as centrally in the area postrema of the CNS, where the chemoreceptor trigger zone (CTZ) for vomiting is located, resulting in the suppression of chemotherapy- and radiotherapy-induced nausea and vomiting. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

The active ingredient in ZOFRAN Injection and ZOFRAN Injection Premixed is ondansetron hydrochloride (HCl), the racemic form of ondansetron and a selective blocking agent of the serotonin 5-HT3 receptor type. Chemically it is (±) 1, 2, 3, 9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1- yl)methyl]-4H-carbazol-4-one, monohydrochloride, dihydrate.

The empirical formula is C18H19N3O•HCl•2H2O, representing a molecular weight of 365.9. Ondansetron HCl is a white to off-white powder that is soluble in water and normal saline. Sterile Injection for Intravenous (I.V.) or Intramuscular (I.M.) Administration: Each 1 mL of aqueous solution in the 2-mL single-dose vial contains 2 mg of ondansetron as the hydrochloride dihydrate; 9.0 mg of sodium chloride, USP; and 0.5 mg of citric acid monohydrate, USP and 0.25 mg of sodium citrate dihydrate, USP as buffers in Water for Injection, USP. Each 1 mL of aqueous solution in the 20-mL multidose vial contains 2 mg of ondansetron as the hydrochloride dihydrate; 8.3 mg of sodium chloride, USP; 0.5 mg of citric acid monohydrate, USP and 0.25 mg of sodium citrate dihydrate, USP as buffers; and 1.2 mg of methylparaben, NF and 0.15 mg of propylparaben, NF as preservatives in Water for Injection, USP. ZOFRAN Injection is a clear, colorless, nonpyrogenic, sterile solution. The pH of the injection solution is 3.3 to 4.0. Sterile, Premixed Solution for Intravenous Administration in Single-Dose, Flexible Plastic Containers: Each 50 mL contains ondansetron 32 mg (as the hydrochloride dihydrate); dextrose 2,500 mg; and citric acid 26 mg and sodium citrate 11.5 mg as buffers in Water for Injection, USP. It contains no preservatives. The osmolarity of this solution is 270 mOsm/L (approx.), and the pH is 3.0 to 4.0.

The flexible plastic container is fabricated from a specially formulated, nonplasticized, thermoplastic co-polyester (CR3). Water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly. Solutions inside the plastic container also can leach out certain of the chemical components in very small amounts before the expiration period is attained. However, the safety of the plastic has been confirmed by tests in animals according to USP biological standards for plastic containers.

 1: Billio A, Morello E, Clarke MJ. Serotonin receptor antagonists for highly emetogenic chemotherapy in adults. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD006272. Review. PubMed PMID: 20091591.

2: Frost F, Dailler F, Duflo F. [Ondansetron: a meta-analysis on its efficacy to prevent postoperative nausea and vomiting after craniotomy in adults and children]. Ann Fr Anesth Reanim. 2010 Jan;29(1):19-24. Epub 2010 Jan 15. French. PubMed PMID: 20080017.

3: Pikó B, Bassam A. [Treatment of tumor therapy-induced nausea and vomiting]. Magy Onkol. 2009 Mar;53(1):39-45. Review. Hungarian. PubMed PMID: 19318325.

4: Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009 Feb;10(2):115-24. Epub 2009 Jan 8. Erratum in: Lancet Oncol. 2010 Mar;11(3)226. PubMed PMID: 19135415.

5: Reddy GK, Gralla RJ, Hesketh PJ. Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis. Support Cancer Ther. 2006 Apr 1;3(3):140-2. PubMed PMID: 18632487.

6: Annemans L, Strens D, Lox E, Petit C, Malonne H. Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium. Support Care Cancer. 2008 Aug;16(8):905-15. Epub 2007 Oct 27. PubMed PMID: 17965891.

7: Olver I, Shelukar S, Thompson KC. Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant. Int J Nanomedicine. 2007;2(1):13-8. Review. PubMed PMID: 17722507; PubMed Central PMCID: PMC2673828.

8: Girish C, Manikandan S. Aprepitant: a substance P antagonist for chemotherapy induced nausea and vomiting. Indian J Cancer. 2007 Jan-Mar;44(1):25-30. Review. PubMed PMID: 17401221.

9: McNulty R. Are all 5-HT3 receptor antagonists the same? J Natl Compr Canc Netw. 2007 Jan;5(1):35-43. PubMed PMID: 17239324.

10: Lordick F, Ehlken B, Ihbe-Heffinger A, Berger K, Krobot KJ, Pellissier J, Davies G, Deuson R. Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany. Eur J Cancer. 2007 Jan;43(2):299-307. Epub 2006 Nov 28. PubMed PMID: 17134890.

11: Navari RM. Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist. Future Oncol. 2006 Oct;2(5):591-602. Review. PubMed PMID: 17026451.

12: National Cancer Institute of Canada Clinical Trials Group (SC19), Wong RK, Paul N, Ding K, Whitehead M, Brundage M, Fyles A, Wilke D, Nabid A, Fortin A, Wilson D, McKenzie M, Ackerman I, Souhami L, Chabot P, Pater J. 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). J Clin Oncol. 2006 Jul 20;24(21):3458-64. PubMed PMID: 16849762.

13: [Achieving optimal antiemetic management]. Krankenpfl J. 2005;43(7-10):226-7. German. PubMed PMID: 16515295.

14: Decker GM, DeMeyer ES, Kisko DL. Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. J Support Oncol. 2006 Jan;4(1):35-41, 52. PubMed PMID: 16444851.

15: Holdsworth MT, Vo-Nguyen T. Employment of substandard antiemetic prophylaxis in recent trials of chemotherapy-induced nausea and vomiting. Ann Pharmacother. 2005 Nov;39(11):1903-10. Epub 2005 Oct 4. Review. PubMed PMID: 16204394.

16: Rubenstein EB. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol. 2004 May;2(5):284-9. Review. PubMed PMID: 16163194.

17: Nathan PC, Tomlinson G, Dupuis LL, Greenberg ML, Ota S, Bartels U, Feldman BM. A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a Bayesian randomized serial N-of-1 trials design. Support Care Cancer. 2006 Mar;14(3):268-76. Epub 2005 Jul 29. PubMed PMID: 16052316.

18: Gralla RJ, de Wit R, Herrstedt J, Carides AD, Ianus J, Guoguang-Ma J, Evans JK, Horgan KJ. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials. Cancer. 2005 Aug 15;104(4):864-8. PubMed PMID: 15973669.

19: Tsukagoshi S; Tokyo Cooperative Oncology Group. [Introduction of novel anti-emetic agent, indisetron hydrochloride, developed recently in Japan]. Gan To Kagaku Ryoho. 2005 Apr;32(4):567-73. Review. Japanese. PubMed PMID: 15853230.

20: Mahesh R, Perumal RV, Pandi PV. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods. Pharmazie. 2005 Feb;60(2):83-96. Review. PubMed PMID: 15739895.

21: Tralongo P, Dimari A, Conti G, Aiello R, Mauceri G. Central nervous system side-effects of 5-HT3-receptor antagonists in elderly cancer patients treated with chemotherapy. Ann Oncol. 2004 Jun;15(6):987-8. PubMed PMID: 15151959.

22: Siddiqui MA, Scott LJ. Palonosetron. Drugs. 2004;64(10):1125-32; discussion 1133-4. Review. PubMed PMID: 15139789.

23: Dando TM, Perry CM. Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs. 2004;64(7):777-94. Review. PubMed PMID: 15025555.

24: de Wit R, Herrstedt J, Rapoport B, Carides AD, Guoguang-Ma J, Elmer M, Schmidt C, Evans JK, Horgan KJ. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur J Cancer. 2004 Feb;40(3):403-10. PubMed PMID: 14746859.

25: Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ; Aprepitant Protocol 052 Study Group. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003 Nov 15;21(22):4112-9. Epub 2003 Oct 14. PubMed PMID: 14559886.

26: Ballatori E, Roila F. Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. Health Qual Life Outcomes. 2003 Sep 17;1:46. Review. PubMed PMID: 14521717; PubMed Central PMCID: PMC212194.

27: Gridelli C. 5-HT3-receptor antagonists in the control of delayed-onset emesis. Anticancer Res. 2003 May-Jun;23(3C):2773-82. Review. PubMed PMID: 12926112.

28: Thomas RJ, Williams M, Garcia-Vargas J. Lessons learned from raltitrexed--quality assurance, patient education and intensive supportive drugs to optimise tolerability. Clin Oncol (R Coll Radiol). 2003 Aug;15(5):227-32. PubMed PMID: 12924450.

29: Navari RM, Koeller JM. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists. Ann Pharmacother. 2003 Sep;37(9):1276-86. Review. PubMed PMID: 12921512.

30: Hesketh PJ, Van Belle S, Aapro M, Tattersall FD, Naylor RJ, Hargreaves R, Carides AD, Evans JK, Horgan KJ. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer. 2003 May;39(8):1074-80. PubMed PMID: 12736106.

31: Wilkowski R, Thoma M, Heinemann V, Rau HG, Wagner A, Stoffregen C, Dühmke E. [Radiochemotherapy with gemcitabine and cisplatin in pancreatic cancer -- feasible and effective]. Strahlenther Onkol. 2003 Feb;179(2):78-86. German. PubMed PMID: 12590317.

32: Börjeson S, Hursti TJ, Tishelman C, Peterson C, Steineck G. Treatment of nausea and emesis during cancer chemotherapy. Discrepancies between antiemetic effect and well-being. J Pain Symptom Manage. 2002 Sep;24(3):345-58. PubMed PMID: 12458116.

33: Lachaine J, Laurier C. Cost-efficacy analysis of ondansetron regimens for control of emesis induced by noncisplatin, moderately emetogenic chemotherapy. Am J Health Syst Pharm. 2002 Oct 1;59(19):1837-46. PubMed PMID: 12374068.

34: Markman MR, Peterson G, Kulp B, Markman M. Effectiveness of serotonin-receptor antagonist antiemetic therapy over successive courses of carboplatin-based chemotherapy. Gynecol Oncol. 2002 Jun;85(3):435-7. PubMed PMID: 12051870.

35: Bernstein BJ, Ong C. Efficacy of a single 8-mg i.v. dose of ondansetron hydrochloride for preventing chemotherapy-induced emesis. Am J Health Syst Pharm. 2002 Apr 1;59(7):650-2. PubMed PMID: 11944605.

36: Dranitsaris G, Leung P, Warr D. Implementing evidence based antiemetic guidelines in the oncology setting: results of a 4-month prospective intervention study. Support Care Cancer. 2001 Nov;9(8):611-8. PubMed PMID: 11762972.

37: Maranzano E. Radiation-induced emesis: a problem with many open questions. Tumori. 2001 Jul-Aug;87(4):213-8. Review. PubMed PMID: 11693797.

38: Walton SM. Advances in use of the 5-HT3 receptor antagonists. Expert Opin Pharmacother. 2000 Jan;1(2):207-23. Review. PubMed PMID: 11249543.

39: Tsavaris N, Kosmas C, Mylonakis N, Bacoyiannis C, Kalergis G, Vadiaka M, Boulamatsis D, Iakovidis V, Kosmidis P. Parameters that influence the outcome of nausea and emesis in cisplatin based chemotherapy. Anticancer Res. 2000 Nov-Dec;20(6C):4777-83. PubMed PMID: 11205218.

40: del Giglio A, Soares HP, Caparroz C, Castro PC. Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials. Cancer. 2000 Dec 1;89(11):2301-8. PubMed PMID: 11147601.

41: Murren JR, DiStasio SA, Lorico A, McKeon A, Zuhowski EG, Egorin MJ, Sartorelli AC, Rappa G. Phase I and pharmacokinetic study of novobiocin in combination with VP-16 in patients with refractory malignancies. Cancer J. 2000 Jul-Aug;6(4):256-65. PubMed PMID: 11038146.

42: Perez EA. 5-HT3 antiemetic therapy for patients with breast cancer. Breast Cancer Res Treat. 1999 Sep;57(2):207-14. Review. PubMed PMID: 10598048.

43: Tsukagoshi S. [Pharmacokinetics of azasetron (Serotone), a selective 5-HT3 receptor antagonist]. Gan To Kagaku Ryoho. 1999 Jun;26(7):1001-8. Japanese. PubMed PMID: 10396331.

44: Le Chevalier T, Monnier A, Douillard JY, Ruffie P, Sun XS, Belli L, Ibrahim N, Bougon N, Bérille J. Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer. Eur J Cancer. 1998 Dec;34(13):2032-6. PubMed PMID: 10070306.

45: Pizzo BA, Pisters KM, Miller VA, Grant SC, Baltzer L, Hinckley L, Kris MG. Oral cisapride for the control of delayed vomiting following high-dose cisplatin. Support Care Cancer. 1999 Jan;7(1):44-6. PubMed PMID: 9926974.

46: Gregory RE, Ettinger DS. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs. 1998 Feb;55(2):173-89. Review. PubMed PMID: 9506240.

47: Du Bois A. [Management of chemotherapy-induced emesis: what is the standard after 20 years of clinical research]. Med Klin (Munich). 1998 Jan;93 Suppl 1:3-17. Review. German. PubMed PMID: 19479418.

48: Cunningham RS. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy. Oncol Nurs Forum. 1997 Aug;24(7 Suppl):33-40. Review. PubMed PMID: 9282379.

49: Lofters WS, Pater JL, Zee B, Dempsey E, Walde D, Moquin JP, Wilson K, Hoskins P, Guevin RM, Verma S, Navari R, Krook JE, Hainsworth J, Palmer M, Chin C. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol. 1997 Aug;15(8):2966-73. PubMed PMID: 9256141.

50: Roila F, Del Favero A. Antiemetics revisited. Curr Opin Oncol. 1997 Jul;9(4):321-6. Review. PubMed PMID: 9251881.

51: Pater JL, Lofters WS, Zee B, Dempsey E, Walde D, Moquin JP, Wilson K, Hoskins P, Guevin RM, Verma S, Navari R, Krook JE, Hainsworth J, Palmer M, Chin C. The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann Oncol. 1997 Feb;8(2):181-5. PubMed PMID: 9093728.

52: Tsukagoshi S. [A new antiemetic ramosetron hydrochloride]. Gan To Kagaku Ryoho. 1997 Feb;24(3):371-80. Review. Japanese. PubMed PMID: 9051143.

53: Tremont-Lukats IW, Teixeira GM. Comparison of Granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer. A randomized controlled trial. Cancer. 1996 Dec 1;78(11):2450-3. PubMed PMID: 8941020.

54: Kris MG, Cubeddu LX, Gralla RJ, Cupissol D, Tyson LB, Venkatraman E, Homesley HD. Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin. Cancer. 1996 Nov 15;78(10):2193-8. PubMed PMID: 8918414.

55: Tavorath R, Hesketh PJ. Drug treatment of chemotherapy-induced delayed emesis. Drugs. 1996 Nov;52(5):639-48. Review. PubMed PMID: 9118814.

56: Priestman TJ. Controlling the toxicity of palliative radiotherapy: the role of 5-HT3 antagonists. Can J Oncol. 1996 Feb;6 Suppl 1:17-22. PubMed PMID: 8853534.

57: Meden H, Meissner O, Conrad A, Kuhn W. Improved control of nausea and emesis with a new bromazepam-containing ondansetron regimen in ovarian cancer patients receiving chemotherapy with carboplatin and cyclophosphamide. Eur J Gynaecol Oncol. 1996;17(2):114-22. PubMed PMID: 8654467.

58: Adams VR, Valley AW. Granisetron: the second serotonin-receptor antagonist. Ann Pharmacother. 1995 Dec;29(12):1240-51. Review. PubMed PMID: 8672830.

59: Franchi M, Donadello N, Zanaboni F, Tusei A, Scorbati E. Oral ondansetron and intravenous dexamethasone in the prevention of cisplatin-induced emesis. A phase II trial in women. Oncology. 1995 Nov-Dec;52(6):509-12. PubMed PMID: 7478441.

60: Olver IN. Assessing the comparative clinical value of tropisetron. Aust N Z J Med. 1995 Oct;25(5):523-7. Review. PubMed PMID: 8588777.

61: Agura ED, Brown MC, Schaffer R, Donaldson G, Shen DD. Antiemetic efficacy and pharmacokinetics of intravenous ondansetron infusion during chemotherapy conditioning for bone marrow transplant. Bone Marrow Transplant. 1995 Aug;16(2):213-22. PubMed PMID: 7581139.

62: Adam Z, Coupková H, Kolek V, Kucera M, Loffelmann L, Martinez A, Nováková M, Průsa P, Reiterer P, Skalová B, et al. Vinorelbine and cisplatin in the treatment of advanced non-small cell lung cancer: results of a multicenter Czech study. Acta Med Austriaca. 1995;22(5):120-4. PubMed PMID: 8651041.

63: Herrstedt J. Development of antiemetic therapy in cancer patients. Acta Oncol. 1995;34(5):637-40. Review. PubMed PMID: 7546831.

64: Kris MG, Pisters KM, Hinkley L. Delayed emesis following anticancer chemotherapy. Support Care Cancer. 1994 Sep;2(5):297-300. Review. PubMed PMID: 8000726.

65: Tonato M, Roila F, Del Favero A. Are there differences among the serotonin antagonists? Support Care Cancer. 1994 Sep;2(5):293-6. Review. PubMed PMID: 8000725.

66: Miyata K, Honda K. [Serotonin (5-HT)3 receptors: antagonists and their pharmacological profiles]. Nippon Yakurigaku Zasshi. 1994 Sep;104(3):143-52. Review. Japanese. PubMed PMID: 7959407.

67: Tyson LB, Kris MG, Baltzer L, Pisters KM, Rigas JR, Clark RA. Randomized phase II trial comparing two versus three doses of ondansetron when used in combination with dexamethasone in patients receiving cisplatin > or = 100 mg/m2. Am J Clin Oncol. 1994 Jun;17(3):269-72. PubMed PMID: 8192116.

68: Kaizer L, Warr D, Hoskins P, Latreille J, Lofters W, Yau J, Palmer M, Zee B, Levy M, Pater J. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1994 May;12(5):1050-7. PubMed PMID: 8164029.

69: Kris MG, Grunberg SM, Gralla RJ, Baltzer L, Zaretsky SA, Lifsey D, Tyson LB, Schmidt L, Hahne WF. Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. J Clin Oncol. 1994 May;12(5):1045-9. PubMed PMID: 8164028.

70: Ignoffo RJ. Granisetron. Cancer Pract. 1994 May-Jun;2(3):229-31. PubMed PMID: 8055027.

71: Tonato M, Roila F, Del Favero A, Ballatori E. Antiemetics in cancer chemotherapy: historical perspective and current state of the art. Support Care Cancer. 1994 May;2(3):150-60. Review. PubMed PMID: 8032700.

72: Cooke CE, Mehra IV. Oral ondansetron for preventing nausea and vomiting. Am J Hosp Pharm. 1994 Mar 15;51(6):762-71. Review. PubMed PMID: 8010314.

73: Baltzer L, Kris MG, Tyson LB, Rigas JR, Pisters KM. The addition of ondansetron to the combination of metoclopramide, dexamethasone, and lorazepam did not improve vomiting prevention in patients receiving high-dose cisplatin. Cancer. 1994 Feb 1;73(3):720-3. PubMed PMID: 8299095.

74: Rowinsky EK, Grochow LB, Ettinger DS, Sartorius SE, Lubejko BG, Chen TL, Rock MK, Donehower RC. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res. 1994 Jan 15;54(2):427-36. PubMed PMID: 8275479.

75: Markman M. When regulatory requirements conflict with ethical study design: the case of oral ondansetron. Cancer Invest. 1994;12(6):654-6. PubMed PMID: 7994600.

76: Kris MG, Baltzer L, Pisters KM, Tyson LB. Enhancing the effectiveness of the specific serotonin antagonists. Combination antiemetic therapy with dexamethasone. Cancer. 1993 Dec 1;72(11 Suppl):3436-42. Review. PubMed PMID: 8242576.

77: Marschner N. Ondansetron in the treatment of nausea and vomiting. Introduction. Anticancer Drugs. 1993 Dec;4 Suppl 2:3-7. Review. PubMed PMID: 8136513.

78: Zoubek A, Kronberger M, Puschmann A, Gadner H. Ondansetron in the control of chemotherapy-induced and radiotherapy-induced emesis in children with malignancies. Anticancer Drugs. 1993 Dec;4 Suppl 2:17-21. Review. PubMed PMID: 8136511.

79: Del Favero A, Roila F, Tonato M. Reducing chemotherapy-induced nausea and vomiting. Current perspectives and future possibilities. Drug Saf. 1993 Dec;9(6):410-28. Review. PubMed PMID: 7510495.

80: Liu RJ. Chemotherapy outcomes in advanced non-small-cell lung carcinoma. Semin Oncol. 1993 Aug;20(4):296-301. Review. PubMed PMID: 8393589.

81: Laplanche A, Gérondeau N. [Role of ondansetron in oncology]. Bull Cancer. 1993 Jul;80(7):568-76. French. PubMed PMID: 8204937.

82: Figg WD, Graham CL, Hak LJ, Dukes GE. Ondansetron: a novel antiemetic agent. South Med J. 1993 May;86(5):497-502. Review. PubMed PMID: 8488393.

83: Levitt M, Warr D, Yelle L, Rayner HL, Lofters WS, Perrault DJ, Wilson KS, Latreille J, Potvin M, Warner E, et al. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. N Engl J Med. 1993 Apr 15;328(15):1081-4. PubMed PMID: 8455665.

84: Kris MG, Clark RA, Tyson LB, Hahne WF, Pisters KM, Gralla RJ. Phase II trial of a single intravenous dose of ondansetron in patients receiving cisplatin > or = 100 mg/m2. Am J Clin Oncol. 1993 Feb;16(1):77-80. PubMed PMID: 8424410.

85: Berry WR, House KW, Lee JT, Plagge PB, Meshad MW, Grapski R. Results of a compassionate-use program using intravenous ondansetron to prevent nausea and vomiting in patients receiving emetogenic cancer chemotherapy. Semin Oncol. 1992 Dec;19(6 Suppl 15):33-7. PubMed PMID: 1485180.

86: Bryson JC. Clinical safety of ondansetron. Semin Oncol. 1992 Dec;19(6 Suppl 15):26-32. Review. PubMed PMID: 1485179.

87: Beck TM. Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials. Semin Oncol. 1992 Dec;19(6 Suppl 15):20-5. PubMed PMID: 1485178.

88: Kris MG, Tyson LB, Clark RA, Gralla RJ. Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis. Cancer. 1992 Aug 15;70(4 Suppl):1012-6. Review. PubMed PMID: 1386282.

89: Perez EA, Gandara DR. Advances in the control of chemotherapy-induced emesis. Ann Oncol. 1992 Aug;3 Suppl 3:47-50. Review. PubMed PMID: 1390317.

90: Finn AL. Toxicity and side effects of ondansetron. Semin Oncol. 1992 Aug;19(4 Suppl 10):53-60. Review. PubMed PMID: 1387251.

91: Kris MG. Phase II trials of ondansetron with high-dose cisplatin. Semin Oncol. 1992 Aug;19(4 Suppl 10):23-7. Review. PubMed PMID: 1387247.

92: Egan AP, Taggart JR, Bender CM. Management of chemotherapy-related nausea and vomiting using a serotonin antagonist. Oncol Nurs Forum. 1992 Jun;19(5):791-5. PubMed PMID: 1535124.

93: Burnette PK, Perkins J. Parenteral ondansetron for the treatment of chemotherapy- and radiation-induced nausea and vomiting. Pharmacotherapy. 1992;12(2):120-31. Review. PubMed PMID: 1533280.

94: Seynaeve C, Verweij J, de Mulder PH. 5-HT3 receptor antagonists, a new approach in emesis: a review of ondansetron, granisetron and tropisetron. Anticancer Drugs. 1991 Aug;2(4):343-55. Review. PubMed PMID: 1665723.

95: Schmoll HJ. Introduction: the clinical challenge. Eur J Cancer. 1991;27 Suppl 1:S1-2. PubMed PMID: 1831627.

96: Milano S, Grélot L, Chen Z, Bianchi AL. Vagal-induced vomiting in decerebrate cat is not suppressed by specific 5-HT3 receptor antagonists. J Auton Nerv Syst. 1990 Nov;31(2):109-18. PubMed PMID: 2290001.

97: Khojasteh A, Sartiano G, Tapazoglou E, Lester E, Gandara D, Bernard S, Finn A. Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study. Cancer. 1990 Sep 15;66(6):1101-5. PubMed PMID: 2144788.

98: Bonneterre J, Chevallier B, Metz R, Fargeot P, Pujade-Lauraine E, Spielmann M, Tubiana-Hulin M, Paes D, Bons J. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. J Clin Oncol. 1990 Jun;8(6):1063-9. PubMed PMID: 2140854.

99: Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med. 1990 Mar 22;322(12):810-6. PubMed PMID: 1689807.

100: Stott JR, Barnes GR, Wright RJ, Ruddock CJ. The effect on motion sickness and oculomotor function of GR 38032F, a 5-HT3-receptor antagonist with anti-emetic properties. Br J Clin Pharmacol. 1989 Feb;27(2):147-57. PubMed PMID: 2523720; PubMed Central PMCID: PMC1379774.

101: Kris MG, Gralla RJ, Clark RA, Tyson LB. Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin. J Natl Cancer Inst. 1989 Jan 4;81(1):42-6. PubMed PMID: 2521184.

102: Marty M, Droz JP, Pouillart P, Paule B, Brion N, Bons J. GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting. Cancer Chemother Pharmacol. 1989;23(6):389-91. PubMed PMID: 2523762.